CPA
ORIC icon

Capital Performance Advisors’s Oric Pharmaceuticals ORIC Stock Holding History

Capital Performance Advisors’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1
Closed -$10 – 1898
2024
Q3 		$10 Buy
+1
New +$10 ﹤0.01% 2883

Other funds holding ORIC

P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Performance Advisors's ORIC Position: Q4 2024 in Review

Capital Performance Advisors sold out of Oric Pharmaceuticals (ORIC) in Q4 2024, closing a stake of 1 share — an estimated $10 sold.

Capital Performance Advisors first reported a position in ORIC in Q3 2024 and held it in 1 quarter. The position peaked at $10 in Q3 2024. 129 funds tracked by Wall St. Rank hold ORIC as of Q4 2024.

  • Capital Performance Advisors reported no remaining Oric Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 1 Oric Pharmaceuticals share in Q4 2024, an estimated $10.
  • Capital Performance Advisors first reported a position in Oric Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Oric Pharmaceuticals position peaked at $10 in Q3 2024.
  • 129 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.